VENTURE CAPITAL:Privately Held Life Sciences Companies Raise $1.5B so Far in April
Biotechs rake in $188 million in series B cash in short week before Easter.
Though Wall Street is turning cautious on biotech, privately held life sciences companies are experiencing a boon in funding for their projects. Almost $1.5 billion in new capital has been committed to these companies during the first three weeks of April, with $1.2 billion of that raised by U.S. companies and almost $1 billion raised globally by companies developing therapeutics, diagnostics, and life sciences tools and technology. Read More